VU0364770 hydrochloride
Code | Size | Price |
---|
TAR-T13317-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T13317-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
VU0364770 hydrochloride is a potent and selective mGlu4 positive allosteric modulator (PAM) (EC50s: 290 nM and 1.1 μM at rat mGlu4 and human mGlu4 receptor, respectively).
CAS:
1414842-70-8
Formula:
C12H10Cl2N2O
Molecular Weight:
269.13
Purity:
0.98
SMILES:
Cl.Clc1cccc(NC(=O)c2ccccn2)c1
References
1. Jones CK, et al. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther. 2012 Feb;340(2):404-21.